OBJECTIVES: In-vitro diagnostics (IVD) are essential for diagnosis, screening and monitoring diseases. IVD’s are emerging everyday but usually at a higher cost. Consequently, a formal health technology assessment (HTA) process to should determine its value. The prioritization to initiate this process is key given the limited resources available for HTA in developing countries. Our aim was to establish the prioritization and ranking of IVD’s for assessment for inclusion or ratification in the Colombian healthcare system. METHODS: Using an adapted prioritization tool from the MoH which included 13 standardized criteria grouped into four domains: population needs, benefits and risks of testing, policy priorities and system costs; we performed two rounds of surveys using online Delphi panels with 64 clinician of the 12 medical specialties pertinent to the 87 IVD’s. The list of IVD’s selected was independently submitted by the National manufacturers association (ANDI). Prioritization and ranking were determined by preference weights and Pareto diagrams. RESULTS: From the 87 IVD tests evaluated, 55 were favorably scored and ranked; the remaining 32 IVD’s were not included in the ranking due to low favorability or lack of information. Highly specialized IVD tests with limited use in subspecialties or for rare conditions were often excluded. Tests evaluated with the highest favorability and ranked in the top quartile were often driven by conditions with high impact on the population which often coincides with policy priorities of the MoH. Costs and benefit-risk ratios seem less relevant. CONCLUSIONS: The use of this methodology, for the first time in Latin America in IVD’s, that integrates expert opinion and standardized criteria for prioritizing and ranking IVD’s to be considered for HTA is feasible and useful. Stakeholder involvement in prioritization and ranking technologies for HTA is particularly important in countries with limited resources to perform HTA for healthcare budget allocations. .